Lawrence Otto Klein Sells 2,452 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 2,452 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total value of $234,680.92. Following the completion of the transaction, the chief executive officer directly owned 923,128 shares of the company’s stock, valued at approximately $88,352,580.88. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lawrence Otto Klein also recently made the following trade(s):

• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Trading Up 1.5%

NASDAQ ORKA opened at $93.55 on Thursday. Oruka Therapeutics, Inc. has a 12 month low of $14.89 and a 12 month high of $115.51. The stock’s 50 day moving average is $96.05 and its 200 day moving average is $73.20. The stock has a market cap of $6.19 billion, a PE ratio of -46.08 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts forecast that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ORKA. Algert Global LLC boosted its stake in shares of Oruka Therapeutics by 3.5% during the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after purchasing an additional 180 shares during the period. Nykredit A S bought a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $29,000. AlphaCentric Advisors LLC grew its stake in shares of Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares during the last quarter. Orion Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the second quarter worth approximately $91,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Oruka Therapeutics by 119.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock worth $156,000 after buying an additional 1,736 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Investors are watching the upcoming EVERLAST-A data covering more than 28 weeks of treatment in psoriasis. Positive durability or efficacy results for ORKA-001 could strengthen confidence in Oruka’s long-acting antibody platform and provide an important near-term catalyst for the stock. EVERLAST-A data catalyst article
• Positive Sentiment: Analyst sentiment remains favorable, with ten Buy ratings versus one Sell rating and a consensus price target of approximately $133, above the recent trading range. Recent targets from firms including BTIG, Wedbush, Mizuho and HC Wainwright range from $120 to $165, supporting the bullish view of Oruka’s pipeline. Oruka analyst ratings
• Neutral Sentiment: Company insiders reported multiple stock sales: CEO Lawrence Klein sold 2,452 shares, SVP Arjun Agarwal sold 10,019 shares across two recent transactions, and Joana Goncalves sold 7,947 shares. The transactions were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding obligations from vested equity awards, making them less indicative of negative views than discretionary selling. Oruka insider sales report
• Negative Sentiment: Oruka remains a loss-making clinical-stage biotechnology company. Its latest quarterly loss of $0.55 per share was wider than the expected $0.51 loss, and analysts anticipate a full-year loss of about $2.42 per share. The valuation therefore remains highly dependent on clinical execution and future trial results.

Analyst Ratings Changes

A number of equities research analysts recently commented on ORKA shares. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Mizuho set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 3rd. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. UBS Group raised their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Wedbush restated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.